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Astrocyte scar formation aids central 
nervous system axon regeneration
Mark a. anderson1*†, Joshua E. Burda1*, Yilong ren1†, Yan ao1, Timothy M. O’Shea1, riki Kawaguchi2, Giovanni coppola2, 
Baljit S. Khakh3, Timothy J. Deming4 & Michael V. Sofroniew1
Transected axons fail to regrow spontaneously across severe tissue 
lesions in the mature mammalian central nervous system (CNS). 
Potential mechanisms include: (i) reduced intrinsic growth capacity 
of mature CNS neurons1–3; (ii) absence of external growth stimulating 
and supporting factors1,4,5; and (iii) presence of external inhibitory 
factors associated with myelin6,7, fibrotic tissue8 or astrocytic scars9. 
Alleviating cellular and molecular mechanisms underlying axon 
regeneration failure is fundamental to improving CNS repair after 
traumatic injury, stroke or degenerative disease.
Astrocytic scars have been regarded as barriers to CNS axon regrowth 
since the mid-twentieth century on the basis of their appearance 
and early reports that attenuating astrocytic scar formation enabled 
spontaneous axon regrowth10,11. Although axon-growth-promoting 
effects of early scar attenuators proved illusory, reports correlat-
ing failed axon regrowth with presence of mature astrocytes12 or 
astrocytic scars9, plus evidence that astrocytes produce chondroitin 
sulfate proteoglycans (CSPGs) that inhibit axon growth in vitro9, led 
to the widespread view that astrocytic scars are critical inhibitors of 
CNS axons and that nullifying this inhibition will lead to spontaneous 
axon regeneration.
Here we tested the hypothesis that astrocytic scar formation 
plays a causal role in the failure of transected mature CNS axons 
to regenerate across severe tissue lesions. We used multiple trans-
genic loss-of-function strategies to ablate scar-forming astrocytes, 
genetically attenuate scar-forming astrocytes or to ablate chronic 
astrocytic scars after severe SCI in adult mice. We quantified the 
effects of these manipulations on (i) spontaneous regeneration of 
three major types of CNS axons; (ii) total CSPG levels; (iii) genome-
wide expression by astrocytes and non-astrocytes in SCI lesions of 
molecules associated with axon growth; and (iv) axon regeneration 
stimulated by conditioning lesions plus delivery via synthetic hydro-
gel depots of known axon-required growth factors missing from 
SCI lesions.
No axon regrowth after preventing scars
We first determined effects of preventing astrocytic scar formation on 
the potential for spontaneous unstimulated axon regeneration through 
severe CNS lesions. After focal traumatic tissue damage, CNS lesions 
comprise central areas of non-neural lesion core tissue surrounded 
by narrow astrocytic scar borders13,14. Astrocytic scar formation is 
complete by two weeks after adult murine SCI and is critically 
dependent on astrocyte proliferation and STAT3 signalling15–18. 
We prevented astrocyte scar formation with two loss-of-function 
transgenic mouse models that either selectively kill proliferating 
scar-forming astrocytes15,16 or delete STAT3 signalling selectively from 
astrocytes17,18, referred to respectively as TK+GCV or STAT3-CKO 
mice (Supplementary Information).
After severe crush SCI, wild-type mice formed dense astrocytic scars 
by two weeks that persisted for eight weeks, whereas TK+GCV and 
STAT3-CKO mice failed to form scars and instead exhibited larger 
areas of non-neural tissue around lesion centres that were essentially 
devoid of astrocytes from two to eight weeks after SCI (Fig. 1a–d, 
Extended Data Fig. 1 and Supplementary Information).
Effects of preventing astrocyte scar formation on axon regeneration 
were quantified in three axonal systems: (i) descending corticospinal 
tract (CST); (ii) ascending sensory tract (AST); and (iii) descending 
serotonergic (5HT) tract, visualized either by axonal tract tracing or 
immunohistochemistry (Fig. 1c, e–i and Supplementary Information). 
As expected after severe SCI in adult wild-type mice, transected CST 
and AST axons both exhibited moderate dieback away from lesion 
centres (Fig. 1c, e, g, h). Preventing astrocytic scar formation in 
either TK+GCV or STAT3-CKO mice failed to result in spontane-
ous regrowth of transected CST or AST axons through SCI lesions, 
and instead significantly increased axonal dieback (Fig. 1c, e, g, h). 
As expected19,20, transected 5HT axons exhibited little dieback from 
lesion centres (Fig. 1f, i). Preventing scar formation in TK+GCV 
or STAT3-CKO mice did not exacerbate dieback of 5HT axons. 
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Nevertheless, although many 5HT axons remained in lesion centres 
devoid of astrocytes, they also failed to regrow (Fig. 1f, i).
Thus, in spite of the essential absence of scar-forming astrocytes 
from SCI lesions for eight weeks after SCI in TK + GCV mice or 
STAT3-CKO mice, there was no spontaneous regeneration of tran-
sected CST, AST or 5HT axons through the lesions. This regrowth 
failure was particularly apparent for AST and 5HT axons, the axonal 
tips of which were often present along or within large areas devoid 
of astrocytes but did not regrow spontaneously through such areas 
(Fig. 1e, f).
No axon regrowth after removing chronic scars
Acute astrocytic scar formation restricts inflammation and preserves 
neural tissue14–18. It has been proposed that after inflammation has 
resolved, chronic astrocytic scars are expendable and detrimen-
tal because they continually prevent axon regeneration. To test this 
hypothesis, we ablated chronic astrocytic scars five weeks after SCI 
with genetically targeted diphtheria toxin receptor and ultra-low 
doses of diphtheria toxin21 (Fig. 2 and Supplementary Information). 
Distribution and specificity of targeting to mature astrocytic scars was 
verified with the genetic reporter tdTomato (Fig. 2b, Extended Data 
Fig. 1c and Supplementary Information). GFAP immunohistochemistry 
verified efficient removal of chronic astrocytic scars (Fig. 2c). Axon 
quantitation ten weeks after SCI showed that transected CST, AST or 
5HT axons all failed to regrow spontaneously through areas depleted 
of chronic astrocytic scars (Fig. 2d–i). Again, this failure was particu-
larly notable for AST and 5HT axons in or along areas devoid of scar- 
forming astrocytes that did not regrow through these areas (Fig. 2e, f). 
We also ablated chronic astrocytic scars and adjacent astrocytes over 
larger areas to reach ‘died-back’ CST and AST axons, but this approach 
caused pronounced tissue degeneration and large lesions (Extended 
Data Fig. 1e) that contained essentially no detectable CST, AST or 5HT 
axons. These findings show that ablating chronic astrocytic scars fails 
to result in spontaneous regrowth of CST, AST or 5HT axons through 
SCI lesions, and that chronic astrocytic scars remain critical for 
sustaining tissue integrity.
Multicellular CSPG production
We next looked for molecular mechanisms that might explain why 
ablating or attenuating astrocytic scars failed to enable spontaneous 
axon regrowth through severe lesions. CSPGs produced by astrocytic 
scars are regarded as the principal inhibitors of axon regeneration9. 
Total CSPG levels determined by dot blot with CS56 antibody9,22 were, 
as expected9, significantly higher in our wild-type SCI lesions, but 
were not significantly reduced by transgenic ablation or disruption of 
astrocytic scar formation (Fig. 3a). Because diverse cells in SCI lesions 
including pericytes, fibroblast lineage cells and inflammatory cells13 
can produce CSPGs23, we examined cellular production of CSPG and 
GFAP and quantified immunohistochemically stained tissue areas. 
In SCI lesions of TK+GCV and STAT3-CKO mice, GFAP area was 
significantly reduced in both grey and white matter compared with 
wild type, whereas CSPG area was not significantly reduced in lesion 
core tissue or in regions of ablated astrocytic scars, which were filled 
with CSPG-positive, GFAP-negative cells (Figs 3b,c, Extended Data 
Fig. 2 and Supplementary Information). These findings show that non- 
astrocyte cells in SCI lesions produce substantive amounts of CSPGs 
Figure 2 | No spontaneous regrowth of CST, AST or 5HT axons after 
ablating chronic astrocyte scars. a, Experiment summary schematic.  
b, Selective targeting of tdTomato reporter to GFAP-positive scar-forming 
astrocytes in 500 μm zone occupied by the astrocytic scar (see Extended 
Data Fig. 1c). c, Diphtheria toxin-mediated ablation of chronic astrocytic 
scar after severe SCI in mice with transgenically targeted diphtheria toxin 
receptor. Dotted lines indicate lesion centre (Cn) and 500 μm on either side 
normally occupied by scar-forming astrocytes in wild-type (WT) mice. 
Boxes show locations of d–f in adjacent sections. d, CST axons are found 
only among GFAP-positive astrocytes proximal to ablated scar. e, AST 
axons are present at the margins of a large area depleted of scar but have 
not regrown (arrows). f, 5HT axons are present within an area depleted  
of scar but have not regrown (arrows). g–i, Numbers (means ± s.e.m.) of 
CST (g), AST (h), or 5HT (i) axons at various distances from SCI lesion 
centres as a percentage of the total number of axons present at 3 mm 
proximal. CST, n = 6 mice; AST and 5HT, n = 5 mice; *P < 0.05 versus  
wild type (ANOVA with Newman–Keuls).
LC
LC
d CST axons AST axons e f 5HT axons 
50 μm
f
d
e
Cn 5
00
 μ
m
LC
CST 
5HT 
Caudal
Rostral
3 mm
Cn LC
AS
AST 
3 mm
a b  AAV-GFAP-Creto mature scar
50
0 
μm
LC
AS
Cn
BDA + GFAP + DAPI CTB + GFAP + DAPI 5HT + GFAP + DAPI tdT + GFAP GFAP + DAPI 
%
 o
f a
xo
ns
0
0
0
0
0
0
20
40
60
80
100
0
–3,000 –2,000 –1,000 0
*
*
*
WT
DT
h AST axons 
Distance from lesion centre (μm)
i 5HT axons 
LC
!!!"
0
0
0
0
0
0
20
40
60
80
100
0
–3,000 –2,000 –1,000 0
*
*
!!!"
0
0
0
0
0
0
20
40
60
80
100
0
–3,000 –2,000 –1,000 0
*
*
*
g CST axons 
Mature scar  
ablation c 
Figure 1 | Preventing astrocytic scar formation does not lead to 
spontaneous regrowth of CST, AST or 5HT axons after SCI.  
a, Experiment summary schematic. Horizontal view of lesion core (LC)  
and astrocytic scar (AS) after SCI. Intercepts of CST, AST or 5HT axons 
with lines drawn at various distances from lesion centre (Cn) were  
counted and expressed as a percentage of all axons 3 mm proximal.  
b, c, e, f, Dotted lines demarcate lesion centre and 500 μm on either side.  
b, d, Area occupied by GFAP-positive scar-forming astrocytes within 
500 μm either side of the lesion centre at 2 or 8 weeks after SCI. n = 6.  
c, e, Arrows depict most-caudal CST axons (biotinylated dextran amine 
tracing) or most-rostral AST axons (choleratoxin B tracing). f, Arrows 
in top images depict most caudally penetrating 5HT axons, boxed areas 
are shown below. In wild-type mice, 5HT axons are surrounded by the 
astrocytic scar (arrowheads). In TK+GCV and STAT3-CKO mice, many 
5HT axons are not in contact with the astrocytic scar (arrows), but have 
not regrown. g–i, Numbers (means ± s.e.m.) of CST (g), AST (h) and  
5HT (i) axons at various distances from the SCI lesion centre as a 
percentage of the total number of axons present 3 mm proximal. CST,  
n = 6 mice; AST and 5HT, n = 5 mice; *P < 0.05 versus wild type  
(ANOVA with Newman–Keuls).
e 
b 
Cn 5
00
 μ
m
LCLC
AS
AS
WT TK+GCV STAT3-CKO 
Astrocytic scar at 2 weeks 
GFAP 
c 
WT TK+GCV STAT3-CKO 
Cn 5
00
 μ
m
AS
AS
LCLC
BDA + GFAP 
CST tracing at 8 weeks 
CST 
5HT 
Caudal
Rostral
3 mm
Cn LC
AS
AST 
3 mm
WT TK+GCV STAT3-CKO 
AS
Cn
50
0 
μm
AST tracing at 8 weeks 
CST axons 8 weeks 
%
 o
f a
xo
ns
0
0
0
0
0
0
20
40
60
80
100
0
–3,000 –2,000 –1,000 0 +1,000
*
*
*
**
Distance from lesion centre (μm)
AST axons 8 weeks 
%
 o
f a
xo
ns
0
0
0
0
0
0
20
40
60
80
100
0
–3,000 –2,000 –1,000 0 +1,000
Distance from lesion centre (μm)
5HT staining at 8 weeks 
LC LC
50
0 
μm
AST ASTAST
Cn
a 
g h 5HT axons 8 weeks 
%
 o
f a
xo
ns
0
0
0
0
0
0
20
40
60
80
100
0
–3,000 –2,000 –1,000 0 +1,000
Distance from lesion centre (μm)
i 
f 
50
0 
μm
WT TK+GCV STAT3-CKO 
Cn
WT
TK+GCV
STAT3-CKO
Astrocyte scar area 
20
40
60
80
0
100
2 week 8 week
G
FA
P
 (%
 o
f a
re
a)
* * *
*
d 
25 μm
5HT + GFAP + DAPI 
AS
CTB + GFAP + DAPI 
*
*
*
*
*
*
*
*
© 2016 Macmillan Publishers Limited. All rights reserved
Article reSeArcH
1 4  a p r i l  2 0 1 6  |  V O l  5 3 2  |  N a T U r E  |  1 9 7
and that preventing astrocytic scar formation fails to reduce total CSPG 
production in SCI lesions.
Genomic dissection of SCI lesions
Numerous molecules attract, repel, support or inhibit axon growth dur-
ing development, and many of these are present in CNS lesions7,24,25. To 
look broadly at molecules produced by astrocytes or non-astrocyte cells 
in SCI lesions that might affect axon regrowth, we conducted genome-
wide RNA sequencing of astrocyte-specific ribosome-associated RNA 
(ramRNA) precipitated via a haemagglutinin tag26 transgenically 
targeted to either wild-type or STAT3-CKO astrocytes, and non- 
precipitated (flow-through) RNA deriving from non-astrocyte 
cells in the same tissue samples (Fig. 4, Extended Data Fig. 3 and 
Supplementary Information).
At two weeks after SCI, astrocytes and non-astrocyte cells in SCI 
lesions exhibited significantly altered expression of many genes in 
both wild-type and STAT3-CKO mice, and wild-type astrocytes 
exhibited expected known changes27 (Extended Data Fig. 4a–d and 
Supplementary Information). Notably, 63% of genes significantly 
regulated by wild-type astrocytes were not significantly altered by 
STAT3-CKO astrocytes after SCI, and STAT3-CKO SCI astrocyte 
transcriptomes clustered more similarly towards uninjured astrocytes 
than towards wild-type SCI astrocytes (Fig. 4c, d).
We analysed 59 molecules reported to negatively or positively modu-
late axon growth in SCI lesions (Extended Data Table 1). In SCI lesions 
from wild-type mice, both astrocytes and non-astrocyte cells expressed 
a majority not only of 28 known axon inhibitors, including specific 
CSPGs, ephrins, netrins, neuropillins, plexins, slits and others, but also 
a majority of 31 known axon permissive molecules, including specific 
CSPGs, laminins, syndecans, glypicans, decorin and others (Fig. 4e). 
Notably, both astrocytes and non-astrocytes downregulated more axon 
inhibitory molecules than were upregulated, and upregulated more than 
three times the number of axon-permissive molecules than were down-
regulated. Preventing astrocytic scar formation in STAT3-CKO mice did 
not significantly decrease the expression by astrocytes or non-astrocytes 
of a single reported inhibitor, whereas eleven were upregulated, and 
significantly increased the expression of two permissive molecules, and 
decreased three, compared to wild-type SCI (Fig. 4e).
In agreement with our immunoblot and immunohistochemical 
CSPG findings (above), various individual CSPG ramRNAs were 
expressed by both astrocytes and non-astrocyte cells in SCI lesions 
(Fig. 4e). Interestingly, aggrecan, the prototypical CSPG used in axon 
growth inhibition studies in vitro9,28, was not detectably expressed 
by scar-forming astrocytes at either the ramRNA or immunohisto-
chemistry of protein levels (Fig. 4e and Extended Data Fig. 5a). Other 
axon-inhibitory CSPGs, brevican, neurocan, versican and phospha-
can, were all expressed by both scar-forming astrocytes and non- 
astrocyte cells in SCI lesions as revealed by RNA analysis (Fig. 4e) 
and confirmed by immunohistochemistry of protein for brevican and 
neurocan (Extended Data Figs 5b and 6a).
CSPGs are diverse with respect to inhibiting or supporting axon 
growth at both protein and sugar-epitope levels29,30. Of the five 
growth-inhibitory CPSGs, wild-type scar-forming astrocytes increased 
above normal only versican ramRNA, and significantly decreased 
neurocan and phosphacan (Fig. 4e). In contrast, ramRNAs of two 
axon-growth- supportive CSPGs, Cspg4 (NG2) and Cspg5 (neuro-
glycan C) (Extended Data Table 1), were significantly upregulated 
by scar-forming astrocytes (Fig. 4e) and both NG2 and CSPG5 clearly 
decorated scar-forming astrocytes, as revealed by immunohisto-
chemistry (Extended Data Fig. 6b, c).
Our genomic findings show that: (i) STAT3-CKO prevents or atten-
uates a majority of genome-wide changes in astrocytes associated with 
astrogliosis and scar formation in wild-type mice; (ii) astrocytes and 
non-astrocyte cells in SCI lesions express a large, diverse mix of axon 
inhibitory and permissive molecules; (iii) non-astrocyte cells in SCI 
lesions substantively express CSPGs; (iv) preventing astrocyte scar 
formation with STAT3-CKO does not reduce expression of CSPGs or 
other inhibitory molecules in SCI lesions; (v) scar-forming astrocytes 
upregulate and substantively express axon-growth-supporting CSPGs, 
indicating that CS56 immune detection of total CSPG levels22 need not 
indicate a purely axon-inhibitory environment; and (vi) scar-forming 
astrocytes and non-astrocyte cells in SCI lesions upregulate multiple 
axon-growth-permissive matrix molecules, including laminins.
Axon regrowth in spite of scar formation
We next stimulated axon growth after SCI in the presence or absence 
of astrocytic scar formation. Developing axons do not grow by default 
but require stimulatory cues31. This requirement may apply also to 
regrowth of transected mature axons. Some transected mature AST 
axons can be stimulated to regrow in severe SCI lesions by activat-
ing neuron intrinsic growth programs with peripheral conditioning 
lesions32–34, and this regrowth can be significantly augmented by cell 
grafts that provide supportive matrix plus the neurotrophic factors NT3 
and BDNF that attract AST axon growth during development35. We 
noted the essential absence of Nt3 and Bdnf expression in our wild-type 
SCI lesions, combined with expression of permissive matrix molecules 
including laminins known to support developing AST axons36 (Fig. 4e 
and Extended Data Table 1). We therefore tested effects of conditioning 
lesions plus local delivery of NT3 and BDNF on AST axon regenera-
tion stimulated in the presence or absence of astrocyte scar formation 
(Fig. 5 and Extended Data Figs 7–9). Because cell grafts modify astro-
cytic scars35 and provide permissive substrates for regrowing axons, 
we delivered NT3 and BDNF via synthetic hydrogel depots that do not 
modify astrocytic scar formation and provide prolonged neurotrophin 
delivery37–39 (Fig. 5d; Supplementary Information).
No AST fibres regrew past astrocytic scars into lesion cores after 
SCI alone or with hydrogel without growth factors (Fig. 5a, j and 
Figure 3 | CSPG production by non-astrocyte cells in SCI lesions 
after ablation or attenuation of astrocytic scars. a, Dot blots (left) and 
quantification (right, mean and s.e.m.) of total CSPGs detected by CS56 
antibody relative to total protein levels (Ponceau). n = 4 mice; *P < 0.05 
versus uninjured (ANOVA with Newman–Keuls). b, CS56 and GFAP 
immunohistochemistry (see Extended Data Fig. 2). AS, astrocytic scar;  
LC, lesion core; g, grey matter; w, white matter. c, Details of boxed areas  
in b showing CSPG production by GFAP-negative cells.
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Extended Data Fig. 7c). Small numbers of AST axons regrew into 
lesion cores in mice with SCI plus conditioning lesions alone, or 
SCI plus NT3 and BDNF without conditioning lesions (Fig. 5j, k 
and Extended Data Fig. 7c). By contrast, mice receiving both condi-
tioning lesions plus NT3 and BDNF exhibited robust axon regrowth 
through and beyond astrocytic scars, and the number of axon inter-
cepts counted at lesion centres averaged over 45% of that in intact sen-
sory tracts 3 mm proximal to lesions (Fig. 5b, j, k and Extended Data 
Fig. 7c). Remarkably, these stimulated AST axons regrew profusely 
through, and past, dense astrocyte scars, and in spite of substantial 
CSPG (Fig. 5b, e–g, Extended Data Figs 7b, c and 8). AST axons stim-
ulated to regrow in SCI lesions were thin and uniformly tracked along 
laminin surfaces, turning and even reversing direction along these 
surfaces as expected of regenerating axons40, whereas AST axons in 
intact gracile–cuneate tracts were coarsely beaded and were not in 
direct contact with laminin (Fig. 5h and Extended Data Fig. 9a–f). 
Hydrogel delivery of anti-CD29 laminin-integrin function-blocking 
antibodies36 together with NT3 and BDNF significantly reduced AST 
axon regrowth in lesion cores by 73%, demonstrating that laminin 
interactions were critical for stimulated AST axon regrowth (Fig. 5i, j, 
Extended Data Fig. 9g–i and Supplementary Information). Lastly, pre-
venting astrocyte scar formation did not augment AST axon regrowth 
stimulated by conditioning lesions plus NT3 and BDNF, but instead 
completely prevented, or significantly attenuated, axon regrowth in 
TK + GCV mice and STAT3-CKO mice, respectively (Fig. 5c, j, k), 
demonstrating that astrocytic scar formation aids, rather than inhibits 
appropriately stimulated AST axon regeneration after SCI.
Discussion
Our findings show that contrary to prevailing dogma, astrocytic scar 
formation is not a principal cause for the failure of injured mature CNS 
axons to regrow across severe CNS lesions and that scar-forming astro-
cytes permit and support robust amounts of appropriately stimulated 
CNS axon regeneration. Although our observations with stimulated 
AST axon regeneration needs extension to other axonal systems, our 
findings are consistent with evidence that: (i) astrocytes can support 
growth of different CNS axons in vivo during development41,42 or 
after mature CNS injury19,43; (ii) genetic activation of axonal growth 
programs by mature neurons leads to axon regeneration across CNS 
lesions only when scar-forming astrocyte bridges are present2,44; and 
(iii) grafts of progenitor-derived astrocytes support axon regeneration 
through non-neural SCI lesion cores45,46.
The predominant mechanistic proposal for astrocytic scar inhi-
bition of axon regeneration is CSPG production9. However, specific 
CSPGs can support or repel axon growth (see Extended Data Table 1). 
We show that scar-forming astrocytes upregulate growth supportive 
CSPG4 and CSPG5, and that both astrocytes and non-astrocytes in SCI 
lesions express multiple axon-growth-supportive molecules, includ-
ing laminins. Axon growth and guidance depend both on intrinsic 
growth potential2,3,31,32,47 and on a balance of extrinsic regulatory cues 
that modulate one another’s effects on growth cones25. Our findings 
show that sustained delivery of required axon-specific growth factors 
not adequately expressed in SCI lesions, combined with activation of 
neuron-intrinsic growth programs, can stimulate robust regrowth of 
transected axons along specifically required supportive matrix cues in 
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Figure 4 | Genomic dissection of astrocytes and non-astrocyte cells 
in SCI lesions. a, Schematic of tissue harvested for RNA sequencing 
(RNAseq). AS, astrocytic scar; LC, lesion core. b, Transgenically-targeted 
haemagglutinin (HA)-tagged ribosome clusters (arrows) among GFAP 
filaments in scar-forming astrocytes (see Extended Data Fig. 3a).  
c, Unsupervised hierarchical clustering dendrogram based on Pearson 
correlations shows that transcriptome profiles of STAT3-CKO SCI 
astrocytes cluster nearer to (and are more similar to) those of uninjured 
as compared to wild-type (WT) SCI astrocytes. d, Numbers and heat 
map of significantly differentially expressed genes (DEGs) in wild-type 
astrocytes after SCI and the comparative differential expression profile of 
that specific cohort of genes in STAT3-CKO SCI astrocytes. Differential 
expression relative to uninjured, false discovery rate (FDR) < 0.1.  
e, Histogram of astrocyte and non-astrocyte expression of axon-growth-
inhibitory or -permissive molecules after SCI shown as mean FPKM 
(fragments per kilobase of transcript sequence per million mapped 
fragments). Asterisks indicate significant differences between astrocytes 
and non-astrocytes, FDR < 0.1. Numbers show significant log2 fold 
differences. Red, upregulated; green, downregulated; NS, non-significant; 
ST3 SCI, STAT3-CKO SCI.
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spite of the presence of inhibitory cues, and that this stimulated axon 
regrowth can occur either in direct contact with scar-forming astro-
cyte processes or independently of astrocyte processes. These obser-
vations provide direct evidence that the requirements for achieving 
axon regeneration across severe CNS lesions, where transected axons 
lack intrinsic and extrinsic conditions for long-distance regrowth, are 
fundamentally different from requirements to achieve local neurite 
outgrowth in intact but reactive perilesional grey matter, where con-
ditions compatible with axon terminal growth and remodelling are 
present and where blocking inhibitory regulators such as CSPGs and 
others produced by astrocytes and other cells may be sufficient to 
promote axon sprouting that might also improve function9,15,24,28,40,48. 
Our findings have important implications for CNS repair strategies by 
demonstrating that rather than being hostile to axon growth, newly 
generated immature scar-forming astrocytes derived after SCI from 
endogenous progenitors18,41,44, and potentially from grafted progeni-
tors45,46, aid axon regeneration and may represent exploitable bridges 
for regrowing axons across severe CNS lesions.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Mice. All non-transgenic, transgenic and control mice used in this study were 
derived from in house breeding colonies backcrossed > 12 generations onto 
C57/BL6 backgrounds. All mice used were young adult females between two and 
four months old at the time of spinal cord injury. All transgenic mice used have 
been previously well characterized or are the progeny of crossing well-characterized 
lines: (1) mGFAP-TK transgenic mice line 7.115,16,49; (2) mGFAP-Cre-STAT3-loxP 
mice generated by crossing STAT3-loxP mice with loxP sites flanking exon 22 
of the STAT3 gene50 with mGFAP-Cre mice line 73.1217,18; (3) loxP-STOP- 
loxP-DTR (diphtheria toxin receptor) mice21; (4) mGFAP-Cre-RiboTag mice 
generated by crossing mice with loxP-STOP-loxP-Rpl22-HA (RiboTag)26 with 
mGFAP-Cre mice line 73.1217,18; (5) loxP-STOP-loxP-tdTomato reporter mice51. 
All mice were housed in a 12-h light/dark cycle in a specific-pathogen-free facility 
with controlled temperature and humidity and were allowed free access to food 
and water. All experiments were conducted according to protocols approved by 
the Animal Research Committee of the Office for Protection of Research Subjects 
at University of California, Los Angeles.
Surgical procedures. All surgeries were performed under general anaesthesia 
with isoflurane in oxygen-enriched air using an operating microscope (Zeiss, 
Oberkochen, Germany), and rodent stereotaxic apparatus (David Kopf, Tujunga, 
CA). Laminectomy of a single vertebra was performed and severe crush spinal 
cord injuries (SCI) were made at the level of T10 using No. 5 Dumont forceps 
(Fine Science Tools, Foster City, CA) without spacers and with a tip width of 
0.5 mm to completely compress the entire spinal cord laterally from both sides for 
5 s16–18. For pre-conditioning lesions, sciatic nerves were transected and ligated 
one week before SCI. Hydrogels were injected stereotaxically into the centre of 
SCI lesions 0.6 mm below the surface at 0.2 μl per minute using glass micropi-
pettes (ground to 50–100 μm tips) connected via high-pressure tubing (Kopf) to 
10-μl syringes under control of microinfusion pumps, two days after SCI52. Tract 
tracing was performed by injection of biotinylated dextran amine 10,000 (BDA, 
Invitrogen) 10% wt/vol in sterile saline injected 4 × 0.4 μl into the left motor cer-
ebral cortex 14 days before perfusion to visualize corticospinal tract (CST) axons, 
or choleratoxin B (CTB) (List Biological Laboratory, Campbell, CA) 1 μl of 1% 
wt/vol in sterile water injected into both sciatic nerves three days before perfu-
sion to visualize ascending sensory tract (AST) axons33. AAV2/5-GfaABC1D-Cre 
(see below) was injected either 3 or 6 × 0.4 μl (1.29 × 1013 gc ml−1 in sterile 
saline) into and on either side of mature SCI lesions two weeks after SCI, or into 
uninjured spinal cord after T10 laminectomy. All animals received analgesic 
before wound closure and every 12 h for at least 48 h post-injury. Animals were 
randomly assigned numbers and evaluated thereafter blind to genotype and 
experimental condition.
AAV2/5-GfaABC1D-Cre. Adeno-associated virus 2/5 (AAV) vector with a min-
imal GFAP promoter (AAV2/5 GfaABC1D) was used to target Cre-recombinase 
expression selectively to astrocytes53–55.
Hydrogel with growth factors and antibodies. Diblock co-polypeptide hydro-
gel (DCH) K180L20 was fabricated, tagged with blue fluorescent dye (AMCA-X) 
and loaded with growth factor and antibody cargoes as described38,39,52. Cargo 
molecules comprised: human recombinant NT3 and BDNF were gifts (Amgen, 
Thousand Oaks, CA, (NT3 Lot#2200F4; BDNF Lot#2142F5A) or were pur-
chased from PeproTech (Rocky Hill, NJ; NT3 405-03, Lot#060762; BDNF 405-02 
Lot#071161). Function blocking anti-CD29 mouse monoclonal antibody was pur-
chased from BD Bioscience (San Diego, CA) as a custom order at 10.25 mg ml−1 
(product #BP555003; lot#S03146). Freeze dried K180L20 powder was reconstituted 
on to 3.0% or 3.5% wt/vol basis in sterile PBS without cargo or with combinations 
of NT3 (1.0 μg μl−1), BDNF (0.85 μg μl−1) and anti-CD29 (5 μg μl−1). DCH mixtures 
were prepared to have G′ (storage modulus at 1 Hz) between 75 and 100 Pascal 
(Pa), somewhat below that of mouse brain at 200 Pa (refs 38,39).
Ganciclovir (GCV), BrdU or DT injections. GCV (Cytovene-IV Hoffman 
LaRoche, Nutley, NJ), 25 mg kg−1 per day dissolved in sterile physiological saline 
was administered as single daily subcutaneous injections starting immediately 
after surgery and continued for the first 7 days after SCI. Bromodeoxyuridine 
(BrdU, Sigma), 100 mg kg−1 per day dissolved in saline plus 0.007 M NaOH, was 
administered as single daily intraperitoneal injections on days 2 through 7 after 
SCI. Diphtheria toxin A (DT, Sigma #DO564) 100 ng in 100 μl sterile saline was 
administered twice daily as intraperitoneal injections for ten days starting three 
weeks after injection of AAV2/5-GfaABC1D-Cre to loxP-DTR mice (which was 
5 weeks after SCI) (see timeline in Extended Data Fig. 1d).
Hindlimb locomotor evaluation, animal inclusion criteria, randomization 
and blinding. Two days after SCI, all mice were evaluated in open field and 
mice exhibiting any hindlimb movements were not studied further. Mice that 
passed this pre-determined inclusion criterion were randomized into experimen-
tal groups for further treatments and were thereafter evaluated blind to their 
experimental condition. At 3, 7, 14 days and then weekly after SCI, hindlimb 
movements were scored using a simple six-point scale in which 0 is no movement 
and 5 is normal walking17.
Histology and immunohistochemistry. After terminal anaesthesia by barbiturate 
overdose mice were perfused transcardially with 10% formalin (Sigma). Spinal 
cords were removed, post-fixed overnight, and cryoprotected in buffered 30% 
sucrose for 48 h. Frozen sections (30 μm horizontal) were prepared using a cry-
ostat microtome (Leica) and processed for immunofluorescence as described16–18. 
Primary antibodies were: rabbit anti-GFAP (1:1,000; Dako, Carpinteria, CA); 
rat anti-GFAP (1:1,000, Zymed Laboratories); goat anti-CTB (1:1,000, List 
Biology Lab); rabbit anti-5HT (1:2,000, Immunostar); goat anti-5HT (1:1,000, 
Immunostar); mouse anti-CSPG22 (1:100, Sigma); rabbit-anti haemaggluti-
nin (HA) (1:500 Sigma); mouse-anti HA (1:3,000 Covance); sheep anti-BrdU 
(1:6,000, Maine Biotechnology Services, Portland, ME); rabbit anti-laminin 
(1:80, Sigma, Saint Louis, MO); guinea pig anti-NG2 (CSPG4) (E. G. Hughes 
and D. W. Bergles56, Baltimore, MA); goat anti-aggrecan (1:200, NOVUS); rabbit 
anti-brevican (1:300, NOVUS); mouse anti-neurocan (1:300, Milipore); mouse 
anti-phosphacan (1:500, Sigma); goat anti-versican (1:200, NOVUS); rabbit 
anti-neurglycan C (CSPG5) (1:200, NOVUS). Fluorescence secondary antibodies 
were conjugated to: Alexa 488 (green) or Alexa 350 (blue) (Molecular Probes), 
or to Cy3 (550, red) or Cy5 (649, far red) all from (Jackson Immunoresearch 
Laboratories). Mouse primary antibodies were visualized using the Mouse-
on-Mouse detection kit (M.O.M., Vector). BDA tract-tracing was visual-
ized with streptavidin-HRP plus TSB Fluorescein green or Tyr-Cy3 (Jackson 
Immunoresearch Laboratories). Nuclear stain: 4′,6′-diamidino-2-phenylindole 
dihydrochloride (DAPI; 2 ng ml−1; Molecular Probes). Sections were coverslipped 
using ProLong Gold anti-fade reagent (InVitrogen, Grand Island, NY). Sections 
were examined and photographed using deconvolution fluorescence microscopy 
and scanning confocal laser microscopy (Zeiss, Oberkochen, Germany).
Axon quantification. Axons labelled by tract tracing or immunohistochemistry 
were quantified using image analysis software (NeuroLucida, MicroBrightField, 
Williston, VT) operating a computer-driven microscope regulated in the x, y and 
z axes (Zeiss) by observers blind to experimental conditions. Using NeuroLucida, 
lines were drawn across horizontal spinal cord sections at SCI lesion centres and 
at regular distances on either side (Fig. 1a) and the number of axons intercepting 
lines was counted at 63× magnification under oil immersion by observers blind 
to experimental conditions. Similar lines were drawn and axons counted in intact 
axon tracts 3 mm proximal to SCI lesions and the numbers of axon intercepts in 
or near lesions were expressed as percentages of axons in the intact tracts in order 
to control for potential variations in tract-tracing efficacy or intensity of immuno-
histochemistry among animals. Two sections at the level of the CST or AST, and 
three sections through the middle of the cord for 5HT, were counted per mouse 
and expressed as total intercepts per location per mouse. To determine efficacy 
of axon transection after SCI, we examined labelling 3 mm distal to SCI lesion 
centres, with the intention of eliminating mice that had labelled axons at this 
location on grounds that these mice may have had incomplete lesions. However, 
all mice that had met the strict behavioural inclusion criterion of no hindlimb 
movements two days after severe crush SCI, exhibited no detectable axons 3 mm 
distal to SCI lesions regardless of treatment group.
Quantification of immunohistochemically stained areas. Sections stained for 
GFAP, CSPG or laminin were photographed using constant exposure settings. 
Single-channel immunofluorescence images were converted to black and white 
and thresholded (Fig. 1d and Extended Data Fig. 2b) and the amount of stained 
area measured in different tissue compartments using NIH ImageJ software. Areas 
are shown in graphs as mean values plus or minus standard error of the means 
(s.e.m.).
Statistics, power calculations and group sizes. Statistical evaluations of repeated 
measures were conducted by ANOVA with post hoc, independent pairwise anal-
ysis as per Newman-Keuls (Prism, GraphPad, San Diego, CA). Power calculations 
were performed using G*Power Software v3.1.9.2 (ref. 57). For quantification of 
histologically derived neuroanatomical outcomes such as numbers of axons or 
percentage of area stained for GFAP or CSPG, group sizes were used that were 
calculated to provide at least 80% power when using the following parameters: 
probability of type I error (α) = 0.05, a conservative effect size of 0.25, 2–8 treat-
ment groups with multiple measurements obtained per replicate. Using Fig. 5j as 
an example, evaluation of n = 5 biological replicates (with multiple measurements 
per replicate) in each of 8 treatment groups provided greater than 88% power.
Dot blot. For dot blot immunoassay of chondroitin sulfate proteoglycans 
(CSPG), spinal cord tissue blocks were lysed and homogenized in standard 
RIPA (radio-immunoprecipitation assay) buffer. LDS (lithium dodecyl sulfate) 
buffer (Life Technologies) was added to the post-mitochondrial supernatant and 
2 μl containing 2 μg μl−1 protein was spotted onto a nitrocellulose membrane 
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(Life Technologies), set to dry and incubated overnight with mouse anti- 
chondroitin sulfate antibody (CS56, 1:1000, Sigma Aldrich), an IgM-monoclonal 
antibody that detects glyco-moieties of all CSPGs22. CS56 immunoreactivity was 
detected on X-ray film with alkaline phosphatase-conjugated secondary antibody 
and chemiluminescent substrate (Life Technologies). Densitometry measure-
ments of CS56 immunoreactivity were obtained using ImageJ software (NIH) and 
normalized to total protein (Poncau S) density58. Densities are shown in graphs as 
mean values plus or minus standard error of the means (s.e.m.).
Isolation, sequencing and analysis of RNA from astrocytes and non-astrocyte 
cells. Two weeks after SCI, spinal cords of wild-type control (GFAP-RiboTag) and 
STAT3-CKO (GFAP-STAT3CKO-RiboTag) mice were rapidly dissected out of the 
spinal canal. The central 3 mm of the lower thoracic lesion including the lesion 
core and 1 mm rostral and caudal were then rapidly removed and snap frozen in 
liquid nitrogen. Haemagglutinin (HA) immunoprecipitation (HA-IP) of astro-
cyte ribosomes and ribosome-associated mRNA (ramRNA) was carried out as 
described26. The non-precipitated flow-through (FT) from each IP sample was 
collected for analysis of non-astrocyte total RNA. HA and FT samples underwent 
on-column DNA digestion using the RNase-Free Dnase Set (Qiagen) and RNA 
purified with the RNeasy Micro kit (Qiagen). Integrity of the eluted RNA was 
analysed by a 2100 Bioanalyzer (Agilent) using the RNA Pico chip, mean sam-
ple RIN = 8.0 ± 0.95. RNA concentration determined by RiboGreen RNA Assay 
kit (Life Technologies). cDNA was generated from 5 ng of IP or FT RNA using 
the Nugen Ovation 2 RNA-Seq Sytstem V2 kit (Nugen). 1 μg of cDNA was frag-
mented using the Covaris M220. Paired-end libraries for multiplex sequencing 
were generated from 300 ng of fragmented cDNA using the Apollo 324 automated 
library preparation system (Wafergen Biosystems) and purified with Agencourt 
AMPure XP beads (Beckman Coulter). All samples were analysed by an Illumina 
NextSeq 500 Sequencer (Illumina) using 75-bp paired-end sequencing. Reads were 
quality controlled using in-house scripts including picard-tools, mapped to the 
reference mm10 genome using STAR59, and counted using HT-seq60 with mm10 
refSeq as reference, and genes were called differentially expressed using edgeR61. 
Individual gene expression levels in the Fig. 4e histogram are shown as mean FPKM 
(fragments per kilobase of transcript sequence per million mapped fragments). 
Additional details of differential expression analysis are described in the legends of 
Fig. 4 and Extended Data Figs 3 and 4. Raw and normalized data have been depos-
ited in the NCBI Gene Expression Omnibus and are accessible through accession 
number GSE76097. To ensure the widespread distribution of these datasets, we 
have created a user-friendly website that enables searching for individual genes of 
interest https://astrocyte.rnaseq.sofroniewlab.neurobio.ucla.edu.
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Extended Data Figure 1 | SCI model schematic, locomotor behavioural 
effects, and AAV vector targeting specificity and effects. a, Schematic 
of severe lateral crush SCI at thoracic level T10 that generates a large 
lesion core (LC) of non-neural tissue surrounded by an astrocytic scar 
(AS) and completely transects descending and ascending axons. b, Open 
field hindlimb locomotor score at various times after SCI assessed using a 
5-point scale where 5 is normal and 0 is no movement of any kind17.  
No significant differences were observed among any of the experimental  
groups at any time point. n = 6 mice at all time points P > 0.5 (ANOVA with 
Newman–Keuls post hoc analysis). WT, wild type. c, Horizontal sections 
through a severe SCI lesion of a representative tdTomato (tdT) reporter 
mouse51 injected with an AAV vector with a minimal Gfap promoter 
regulating Cre (AAV2/5-GfaABC1D-Cre) into the lesion at two weeks after 
SCI and perfused at three weeks. tdTomato labelling demonstrates that 
this AAV2/5-GfaABC1D-Cre efficiently and specifically targets GFAP-
positive astrocytes. In this mouse, the amount AAV2/5-GfaABC1D-Cre 
injected was intentionally titrated on the basis of previous trial and error 
to target primarily the astrocytic scar border in an approximately 500 μm 
zone immediately abutting the SCI lesion core. High-magnification 
analysis of individual fluorescence channels stained for tdTomato plus 
various cell markers shows the specificity of Cre activity targeting to cells 
expressing the astrocyte marker, GFAP, but not to cells expressing either 
the neuronal marker, NeuN, or the mature oligodendrocyte marker, GSTπ. 
AAV2/5-GfaABC1D-Cre was prepared using a previously described and 
well-characterized cloning strategy53–55. d, Open field hindlimb locomotor 
scores at various times after SCI. There was no difference in scores of 
control mice and loxP-STOP-loxP-DTR (diphtheria toxin receptor) mice 
that received AAV2/5-GfaABC1D-Cre before injections of diphtheria 
toxin (DT). Five weeks after DT injections, loxP-DTR mice that received 
AAV2/5- GfaABC1D-Cre exhibited a slightly, but significantly, lower 
locomotor score. Hindlimb locomotion was assessed using a 5-point 
scale where 5 is normal and 0 is no movement of any kind17. n = 6 mice 
per group; *P < 0.05 versus wild-type (ANOVA with Newman–Keuls). 
e, GFAP immunohistochemistry of a sagittal section after ablation of a 
chronic astrocytic scar plus adjacent astrocytes. DT was administered to a 
transgenic mouse expressing DTR targeted selectively to astrocytes around 
a severe SCI. In this case, the amount of AAV2/5-GfaABC1D-Cre injected 
was titrated to target not only primarily the astrocytic scar border but also 
adjacent astrocytes spread over approximately 2 mm on either side of the 
centre (Cn) of the SCI lesion core (LC). Note the profound degeneration of 
neural tissue resulting from the selective ablation of the chronic astrocytic 
scar plus adjacent astrocytes after SCI.
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Extended Data Figure 2 | Single-channel CSPG and GFAP 
immunofluorescence and stained area quantification. a, Individual 
fluorescence channels of CS56 and GFAP immunohistochemistry from 
horizontal sections of uninjured mice and at two weeks after severe SCI 
shown in Fig. 3b. Sections are taken from wild-type (WT) mice and mice 
with transgenic ablation (TK+GCV) or attenuation (STAT3-CKO) of 
astrocytic scar formation. b, Example of black and white thresholding of 
single channels of immunofluorescence staining for image analysis  
to quantify (using NIH Image J software) the amount of CSPG- or  
GFAP-stained area in different tissue compartments in SCI lesions.  
Boxes denote areas quantified to obtain values for lesion core (LC) and  
grey (g) or white (w) matter in astrocytic scar (AS) or equivalent regions 
in uninjured tissue. Graphs show percentage of areas (means ± s.e.m.) 
stained for CSPG or GFAP determined using ImageJ. n = 4 (wild type 
mice); n = 6 (TK+GCV and STAT3-CKO mice); #P < 0.05 versus 
uninjured white matter; *P < 0.05 versus uninjured grey matter in same 
experimental group (ANOVA with Newman–Keuls); ^P < 0.05 versus 
equivalent anatomical region in wild-type (ANOVA with Newman–Keuls).
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Extended Data Figure 3 | See next page for caption. 
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Extended Data Figure 3 | Specificity of haemagglutinin targeting to 
astrocytes and enrichment of haemagglutinin immunoprecipitation for 
astrocyte-specific RNA transcripts. a, Individual fluorescence channels 
of immunohistochemistry for transgenically targeted haemagglutinin 
(HA) plus various cell markers showing the specificity of HA targeting to 
cells expressing the astrocyte marker, GFAP, and not to cells expressing 
either the neuronal marker, NeuN, or the mature oligodendrocyte marker, 
GSTπ, in uninjured grey and white matter and in astrocytic scars at 2 
weeks after SCI. b, CNS-cell-type-specific gene transcript enrichment of 
ribosome-associated mRNA (ramRNA) isolated from wild-type (WT) 
uninjured spinal cord by HA immunoprecipitation (HA-IP). Differential 
expression analysis by RNA-seq indicates significant enrichment (red) 
for astrocyte-specific gene transcripts, and de-enrichment (green) for 
gene transcripts enriched in other CNS cell types, FDR < 0.1. A log2 scale 
is used so that positive and negative differences are directly comparable. 
The mean numerical enrichment of three quintessential astrocyte genes, 
Gfap, Aldh1l1 and Aqp4, is 25-fold greater in HA samples than in flow-
through samples. c, Gene transcript enrichment of HA-IP ramRNA 
relative to P7 mouse primary cortical astrocytes103. Of the 200 most highly 
expressed genes previously described103 for post-natal mouse cortical 
astrocytes, 71.5% (red line) are at least fourfold enriched (blue line) in 
HA-IP ramRNA isolated from uninjured spinal cord relative to flow 
through RNA from non-astrocyte cells. d, Pearson correlation plots of 
total normalized RNA-seq reads from individual biological replicates for 
each treatment condition. Correlation colouring indicates little (white) to 
high (red) similarity. n = 4 mice each for uninjured controls and wild-type 
SCI (SCI-WT); n = 3 mice for STAT3-CKO SCI (SCI-STAT3). FDR < 0.1 
for differential expression and enrichment analysis. Raw and normalized 
data have been deposited in the NCBI Gene Expression Omnibus and 
are accessible through GEO Series accession number GSE76097 and via 
a searchable, open-access website https://astrocyte.rnaseq.sofroniewlab.
neurobio.ucla.edu.
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Extended Data Figure 4 | Comparison of genomic data from astrocytes 
and non-astrocyte cells from WT and STAT3-CKO mice after SCI. 
a, Heat maps depicting all significantly differentially expressed genes 
(DEG), as determined by RNA-seq, for wild-type (WT) and STAT3-CKO 
astrocytes and non-astrocytes from independent biological replicates two 
weeks after SCI relative to uninjured wild-type control. Red upregulated, 
green downregulated. b, Total numbers and Venn diagrams of significant 
DEGs in wild-type and STAT3-CKO astrocytes and non-astrocytes two 
weeks after SCI relative to uninjured control. Red and green numerical 
values indicate significantly upregulated and downregulated genes, 
respectively. c, Comparison of altered gene expression in our SCI-reactive 
astrocytes and previously reported forebrain stroke-reactive astrocytes27. 
Of the 200 most highly elevated genes in forebrain astrocytes one week 
following stroke27, 58.5% (red line) are also significantly elevated in 
astrocytes after SCI, relative to uninjured. d, Comparison of expression by 
wild-type SCI and STAT3-CKO SCI reactive astrocytes of a selected cross-
section of genes that are highly regulated after SCI by wild-type reactive 
astrocytes. Many of the regulated genes exhibit changes that are expected 
and implicated in wild-type reactive astrogliosis mechanisms and roles, 
and some of the changes appear to be newly identified in this context. Note 
that many of the genes are not regulated or exhibit attenuated changes 
in STAT3-CKO SCI astrocytes. n = 4 mice each for uninjured and wild-
type SCI; n = 3 mice for STAT3-CKO SCI (SCI-STAT3). FDR < 0.1 for 
differential expression and enrichment analysis.
© 2016 Macmillan Publishers Limited. All rights reserved
Article reSeArcH
Extended Data Figure 5 | Immunohistochemistry of specific CSPGs. 
a, Absence of aggrecan (ACAN) production by scar-forming astrocytes. 
Images show individual fluorescence channels of ACAN and GFAP 
immunohistochemistry from horizontal sections two weeks after severe 
SCI in a representative wild-type (WT) mouse. Boxes denote areas 
of astrocytic scar (AS) or uninjured tissue (Uninj) shown at higher 
magnification. Note that ACAN is: (i) heavily present in the perineuronal 
nets that surround neurons in uninjured tissue; (ii) almost absent from 
astrocytic scar and lesion core (LC); and (iii) not detectably produced 
by newly generated scar-forming astrocytes (arrows). b, Brevican 
(BCAN) production by scar-forming astrocytes and non-astrocyte cells. 
Images show individual fluorescence channels of BCAN and GFAP 
immunohistochemistry from horizontal sections two weeks after severe 
SCI, in wild-type mice and mice with transgenic ablation (TK+GCV) or 
attenuation (STAT3-CKO) of astrocytic scar formation. Note that BCAN 
is produced both by GFAP-positive scar-forming astrocytes (arrowheads) 
and by non-astrocyte cells (arrows).
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Extended Data Figure 6 | Immunohistochemistry of specific CSPGs. 
a, Neurocan (NCAN) production by scar-forming astrocytes and 
non-astrocyte cells. Images show individual fluorescence channels of 
NCAN and GFAP immunohistochemistry from horizontal sections two 
weeks after severe SCI, in a representative wild-type (WT) mouse. Box 
denotes area of lesion core (LC) and astrocytic scar (AS) shown at higher 
magnification. Note that NCAN is produced both by GFAP-positive 
scar-forming astrocytes and by non-astrocyte cells (arrows) in the lesion 
core. b, NG2 (CSPG4) production by newly proliferated scar-forming 
astrocytes. Images show individual channels and various combinations 
of immunofluorescence staining for NG2, GFAP, tdTomato (tdT), BrdU 
(proliferation marker) and DAPI showing astrocytes in a mature SCI 
scar. The images are representative of findings from tdTomato-reporter 
mice51 injected with AAV2/5-GfaABC1D-Cre vector53 into multiple sites 
of the uninjured spinal cord to label mature astrocytes. Three weeks after 
AAV2/5-GfaABC1D-Cre injection, the mice received a severe SCI and 
were administered BrdU from days 2–7 after SCI. The mice were perfused 
after two weeks after SCI. Images comparing individual fluorescence 
channels show that astrocytes labelled 1 and 3: (i) incorporated BrdU  
and thus are newly proliferated after SCI; (ii) express the tdTomato 
reporter; (iii) express GFAP, the prototypical marker of reactive and  
scar-forming astrocytes; and (iv) express NG2 both intracellularly  
and along their cell surfaces. In contrast, astrocyte number 2 is also  
BrdU-labelled and expresses both tdTomato and GFAP, but does not 
appear to express detectable levels of NG2. c, CSPG5 (Neuroglycan C) 
production by scar-forming astrocytes. Images show individual channels 
and various combinations of immunofluorescence staining for CSPG5 
or GFAP. Note that CSPG5 is present within and along the processes of 
GFAP-positive scar-forming astrocytes (arrows).
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Extended Data Figure 7 | Specificity and effects of treatments to 
stimulate AST axon regrowth after SCI. a, BDNF and NT3 treatment 
does not alter the appearance or density of astrocyte scars in wild-type 
(WT) or STAT3-CKO mice. Images show horizontal sections of mice at 
two weeks after SCI or after SCI followed by delayed injection of hydrogel 
only (as a control) or hydrogel releasing NT3 and BDNF. Top images show 
GFAP immunofluorescence; boxed area denotes size of areas taken from 
multiple locations in the astrocytic scar (AS) for GFAP area quantification 
shown in graph. n = 5 mice per group; NS, P > 0.05 (ANOVA with 
Newman–Keuls). Bottom images show brightfield immunohistochemistry 
simultaneously of GFAP+TK to stain both astrocyte cell processes (GFAP) 
and cell bodies (TK) in mGFAP-TK transgenic mice for quantification 
of astrocyte cell numbers shown in graph. For these experiments the 
transgene-derived TK is used as a reporter protein that efficiently labels 
astrocyte cell bodies and thereby improves cell quantification18 and 
the mice were not given GCV. n = 4 mice per group; *P < 0.05 versus 
uninjured (ANOVA with Newman–Keuls); NS, P > 0.05 (ANOVA with 
Newman–Keuls). b, AST axon regrowth through scar-forming astrocytes 
and CSPGs in SCI lesions. Images show individual channels and various 
combinations of immunofluorescence staining for CTB, GFAP and CS56 
to detect total CSPGs from a wild-type mouse after SCI followed by 
delayed injection of a hydrogel depot releasing NT3 and BDNF, shown as 
multichannel image in Fig. 5e. Arrows denote robust regrowth of many 
AST axons along, through and past scar-forming astrocytes into and 
through the lesion core. Note that the stimulated axons are regrowing 
through CSPG containing areas in the astrocyte scar and lesion core. 
Boxed area is shown at higher magnification in Extended Data Fig. 8.  
c, Graph shows numbers of AST axons at various distances past the 
proximal border of the astrocytic scar under different conditions. n = 5 per 
group; *P < 0.001 significant difference SCI+CL+BDNF+NT3 versus all 
other groups (ANOVA with post-hoc Newman–Keuls).
© 2016 Macmillan Publishers Limited. All rights reserved
ArticlereSeArcH
Extended Data Figure 8 | AST axon regrowth through scar-forming 
astrocytes and CSPGs in SCI lesions. a, b, Images show individual 
channels and various combinations of immunofluorescence staining for 
CTB, GFAP and CS56 to detect total CSPGs from a wild-type (WT) mouse 
after SCI followed by delayed injection of a hydrogel depot releasing NT3 
and BDNF, shown as multichannel images in Fig. 5f, g. Arrows in a denote 
robust regrowth of many AST axons along, through and past scar-forming 
astrocytes into and through the lesion core; note that the stimulated axons 
are regrowing through CSPG containing areas in the astrocytic scar and 
lesion core. b, High-magnification orthogonal images of axons in three 
visual planes. Arrows in b denote AST regrowing axons tracking along 
CSPG-positive and GFAP-negative structures. Arrowheads in b denote 
AST axons tracking along GFAP-positive and CSPG-positive astrocyte 
processes, passing from one astrocyte process to another.
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Extended Data Figure 9 | AST axon regrowth in SCI lesions is 
dependent on laminin. a–g, Tract tracing of AST axons using CTB 
and laminin immunohistochemistry. a–c, Same fields imaged for CTB 
alone (a1–c1), or CTB plus laminin (a2–c2). a, d, Intact gracile–cuneate 
tract (GCT). b, SCI only. c, f, SCI plus conditioning lesion (CL) plus 
hydrogel with growth factors. e, SCI plus conditioning lesion. g, SCI plus 
conditioning lesion plus hydrogel with growth factors and anti-CD29. 
d–g, High-magnification orthogonal images of axons in three visual 
planes. Arrows indicate regrowing axons in direct contact with laminin. 
Arrowheads indicate axons not in direct contact with laminin in the 
intact GCT (d) or with anti-CD29 treatment (g). Note the difference in 
appearance of axons in the intact gracile–cuneate tract (GCT), which are 
independent of laminin, compared with regrowing axons in lesion core 
(LC), which track along laminin. h, Axon length per tissue volume (means 
± s.e.m.) in intact GCT or in SCI lesions under different conditions. Intact 
GCT values were not included in ANOVA comparison of other 3 groups. 
i, Percentages (means ± s.e.m.) of AST axon length in direct contact with 
laminin under different conditions. n = 5 mice per group; *P < 0.001 
(ANOVA with post-hoc Newman–Keuls); NS, not significant (ANOVA 
with post-hoc Newman–Keuls).
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extended data Table 1 |  Axon growth inhibitory molecules and axon growth permissive molecules
This table lists the gene abbreviations and full names and of the 59 axon-growth-modulating molecules whose gene expression levels are presented in Fig. 4. The table also summarizes literature 
providing evidence for the axon-growth-inhibitory or -permissive effects of each molecule. Refs 62–102 are cited in this table.
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